Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 3/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 4/20 | 0.36 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 4/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL703979 | 1.00 | CRHR1 (0.39) | CRHR1PTGDR2HCRTR1HCRTR2TRPV4 | |
| SCHEMBL702628 | 0.90 | TRPM2 (0.41) | CRHR1HCRTR1HCRTR2TRPV4BTK | |
| SCHEMBL702629 | 0.90 | TRPM2 (0.41) | CRHR1HCRTR1HCRTR2TRPV4BTK | |
| SCHEMBL701622 | 0.87 | HCRTR1 (0.36) | PTGDR2HCRTR1HCRTR2 | |
| SCHEMBL701623 | 0.87 | HCRTR1 (0.36) | PTGDR2HCRTR1HCRTR2 | |
| SCHEMBL701282 | 0.84 | L3MBTL1 (0.39) | PTGDR2PTGDRTBXA2R | |
| SCHEMBL701281 | 0.84 | L3MBTL1 (0.39) | PTGDR2PTGDRTBXA2R | |
| SCHEMBL733670 | 0.84 | LTA4H (0.35) | PTGDR2 | |
| SCHEMBL733669 | 0.84 | LTA4H (0.35) | PTGDR2 | |
| SCHEMBL700546 | 0.83 | L3MBTL1 (0.36) | PTGDR2PTGDRTBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124641-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | claimed |
| EP-2307382-B1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2011-12-21 | — | — | EP | claimed |
| US-20100016368-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI | 2010-01-21 | — | — | US | claimed |
| US-8268870-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268870-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268870-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120095053-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI (CN) | 2012-04-19 | — | — | US | disclosed |
| US-20120095053-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI (CN) | 2012-04-19 | — | — | US | disclosed |
| US-20120095053-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI (CN) | 2012-04-19 | — | — | US | disclosed |
| US-8124641-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124641-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124641-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2307382-B1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2011-12-21 | — | — | EP | disclosed |
| US-20100016368-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI | 2010-01-21 | — | — | US | disclosed |
| US-20100016368-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI | 2010-01-21 | — | — | US | disclosed |
| US-20100016368-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095053-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | HRH2, HRH1, HRH4 | CRHR1 110/4885PTGDR2 15/4885HCRTR1 320/4885 |
| US-20100016368-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | HRH2, HRH1, HRH4 | CRHR1 110/4885PTGDR2 15/4885HCRTR1 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.